Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis

Abstract

BackgroundThe treatment of hepatitis C (HCV) infections has significantly changed in the past few years due to the introduction of direct-acting antiviral agents (DAAs). DAAs could improve the sustained virological response compared to pegylated interferon with ribavirin (PR). However, there has been no evidence from randomized controlled trials (RCTs) that directly compare the efficacy among the different regimens of DAAs.AimTherefore, we performed a systematic review and network meta-analysis aiming to compare the treatment efficacy between different DAA regimens for treatment naïve HCV genotype 1.MethodsMedline and Scopus were searched up to 25th May 2015. RCTs investigating the efficacy of second generation DAA regimens for treatment naïve HCV genotype 1 were eligible for the review. Due to the lower efficacy and more side effects of first generation DAAs, this review included only second generation DAAs approved by the US or EU Food and Drug Administration, that comprised of simeprevir (SMV), sofosbuvir (SOF), daclatasvir (DCV), ledipasvir (LDV), and paritaprevir/ritonavir/ombitasvir plus dasabuvir (PrOD). Primary outcomes were sustained virological response at weeks 12 (SVR12) and 24 (SVR24) after the end of treatment and adverse drug events (i.e. serious adverse events, anemia, and fatigue). Efficacy of all treatment regimens were compared by applying a multivariate random effect meta-analysis. Incidence rates of SVR12 and SVR24, and adverse drug events of each treatment regimen were pooled using ‘pmeta’ command in STATA program.ResultsOverall, 869 studies were reviewed and 16 studies were eligible for this study. Compared with the PR regimen, SOF plus PR, SMV plus PR, and DVC plus PR regimens yielded significantly higher probability of having SVR24 with pooled risk ratios (RR) of 1.98 (95% CI 1.24, 3.14), 1.46 (95% CI: 1.22, 1.75), and 1.68 (95% CI: 1.14, 2.46), respectively. Pooled incidence rates of SVR12 and SVR24 in all treatment regimens without PR, i.e. SOF plus LDV with/without ribavirin, SOF plus SMV with/without ribavirin, SOF plus DCV with/without ribavirin, and PrOD with/without ribavirin, (pooled incidence of SVR12 ranging from 93% to 100%, and pooled incidence of SVR24 ranging from 89% to 96%) were much higher than the pooled incidence rates of SVR12 (51%) and SVR24 (48%) in PR alone. In comparing SOF plus LDV with ribavirin and SOF plus LDV without ribavirin, the chance of having SVR12 was not significantly different between these two regimens, with the pooled RR of 0.99 (95% CI: 0.97, 1.01). Regarding adverse drug events, risk of serious adverse drug events, anemia and fatigue were relatively higher in treatment regimens with PR than the treatment regimens without PR. The main limitation of our study is that a subgroup analysis according to dosages and duration of treatment could not be performed. Therefore, the dose and duration of recommended treatment have been suggested in range and not in definite value.ConclusionsBoth DAA plus PR and dual DAA regimens should be included in the first l...

The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver

“…Given the markedly improved efficacy, tolerability and safety of regimens that combine various directacting antiviral agents compared with regimens containing interferon, all patients would benefit from interferonfree therapy. 42,46,58,59 Therefore, interferonfree regimens are recommended as first line therapy for all indications.…”

Clinical effectiveness, cost effectiveness and acceptability of community‐based treatment of hepatitis C virus infection: A mixed method systematic review

“…In a systematic review on studies among people who inject drug (PWID) in Europe median of SVR was 55% ranged from 19% to 88% for PEG‐IFN plus RBV regimen . In a systematic review SVR12 among treatment naïve HCV genotype 1 in all DAA regimens without Peg‐IFN plus RBV ranged from 93% to 100% and in patients who received Peg‐IFN plus RBV was 48% . Two systematic reviews on interferon free treatment reported SVR12 in a range from 80% to 96% …”

Treatment of HCV Infection by a Combination of Sofosbuvir and Daclatasvir

“…Как правило, препараты ППД назначают в комбинациях -в виде двой-ной, тройной терапии, монотерапия не дает удовлетвори-тельных результатов. Для усиления эффекта препараты ППД также сочетают с комплексным ингибитором проте-аз ритонавиром, в качестве дополнительных компонентов в схемы могут включаться рибавирин (РИБ) и ПЭГ-ИФН, хотя это влечет рост частоты нежелательных явлений, особенно астенического синдрома и анемии [5].…”